Guttman-Yassky E, Blauvelt A, Eichenfield L, Paller A, Armstrong A, Drew J, Gopalan R, Simpson E. Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. J of Skin [Internet]. 2019Nov.9 [cited 2024Oct.26];3:S41. Available from: https://skin.dermsquared.com/skin/article/view/768